Evidence map›Paper›PMID 27806712›Full record

ArticleBMC public health2016

The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy.

Fabio Mesquita, Melina Erica Santos, Adele Benzaken, Renato Girade Corrêa, Elisa Cattapan, Leandro Soares Sereno, Marcelo Contardo Moscoso Naveira

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in BMC public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Aspects that facilitate access to care for viral hepatitis: An evaluative research.Sao Paulo medical journal = Revista paulista de medicina · 2024
    Article
  3. Article
  4. Article
  5. The Elimination of Hepatitis C as a Public Health Threat.Cold Spring Harbor perspectives in medicine · 2020
    Review
  6. Article
  7. Innovative strategies for the elimination of viral hepatitis at a national level: A country case series.Liver international : official journal of the International Association for the Study of the Liver · 2019
    Review
  8. Hepatitis C elimination: a Public Health Perspective.Current treatment options in gastroenterology · 2019
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fabio MesquitaDepartment of STI, AIDS and Viral Hepatitis, Secretariat of Health Surveillance, Ministry of Health, Setor Administrativo Federal Sul 02-Bloco F-Ed. Premium Torre I, Brasília, 70070-600, Federal District, Brazil.
Melina Erica SantosDepartment of STI, AIDS and Viral Hepatitis, Secretariat of Health Surveillance, Ministry of Health, Setor Administrativo Federal Sul 02-Bloco F-Ed. Premium Torre I, Brasília, 70070-600, Federal District, Brazil.
Adele BenzakenDepartment of STI, AIDS and Viral Hepatitis, Secretariat of Health Surveillance, Ministry of Health, Setor Administrativo Federal Sul 02-Bloco F-Ed. Premium Torre I, Brasília, 70070-600, Federal District, Brazil.
Renato Girade CorrêaDepartment of STI, AIDS and Viral Hepatitis, Secretariat of Health Surveillance, Ministry of Health, Setor Administrativo Federal Sul 02-Bloco F-Ed. Premium Torre I, Brasília, 70070-600, Federal District, Brazil.
Elisa CattapanDepartment of STI, AIDS and Viral Hepatitis, Secretariat of Health Surveillance, Ministry of Health, Setor Administrativo Federal Sul 02-Bloco F-Ed. Premium Torre I, Brasília, 70070-600, Federal District, Brazil.
Leandro Soares SerenoPan American Health Organization, World Health Organization, Avenida das Nações-Setor de Embaixadas Norte, Lote 19, Brasília, 70312-970, Federal District, Brazil.
Marcelo Contardo Moscoso NaveiraDepartment of STI, AIDS and Viral Hepatitis, Secretariat of Health Surveillance, Ministry of Health, Setor Administrativo Federal Sul 02-Bloco F-Ed. Premium Torre I, Brasília, 70070-600, Federal District, Brazil. marcelo.naveira@aids.gov.br.
Ministério da Saúde · BRPan American Health Organization (Brasil) · BR

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundHepatitis C affects over 185 million people around the world. This silent disease is responsible for up to 700,000 deaths per year. Despite the scientific revolution in diagnosis and treatment, hepatitis C control remains a huge challenge due to the cost of effective medications. In response to the global outcry of hepatitis epidemic and the need to improve the nation's public health response, the Ministry of Health of Brazil revolutionized hepatitis C treatment by incorporating highly effective drugs that can be accessed through sustainable and universal means. DISCUSSION: This paper describes the unique process of implementing evidence-informed policy to respond to hepatitis C epidemic through the update of hepatitis C treatment in Brazil based on the estimate of disease prevalence, current international guidelines, and the cost-effectiveness impact in the Brazilian Unified Health System. Through a debate of an experience report, the authors underlie the strategic plan implemented according to the situation analysis that emphasized the need to improve its current response over a relatively short-term period. The comprehensive response is detailed comprising three main objectives: improve treatment outcomes by evaluating and incorporating new and effective medications at a sustainable price; elaborate on clinical guidelines to treat hepatitis C patients; and develop awareness and diagnosis campaigns targeted at the population of interest. In this scenario, Brazil was able to obtain an unprecedented discount for a high-medium income country; provided treatment to more than 7000 individuals in the last 2 months of 2015; and expects to treat 38,000 new patients in 2016. The remarkable process applied in Brazil was developed according to epidemiological data and scientific evidence, and it was motivated by the engagement of the country in the Sustainable Development Goals, which may inspire other developing countries to identify ways to achieve these goals by 2030.

Indexed as

EpidemicsHealth PolicyAntiviral AgentsBrazilHepatitis CHumansPublic Health PracticeAntiviral AgentsHealth accessHepatitis CInterferon-free

Identifiers

PMID27806712
PMCPMC5094040
OpenAlexW2546653997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.